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Abstract: Cardiovascular diseases have such a devastating and increasing impact on the entire world population. In the 
last decade, sex differences have been found in the epidemiology, pathophysiology, treatment, and resolution of these 
pathologies. Therefore, research is focused on improving the knowledge of the mechanisms underlying these discrepancies. 
In this minireview we summarize some of the main processes that are involved in the development of cardiovascular 
diseases, pointing out the major differences between male and female. We discuss disparities in the exposure to risk factors, 
in the electrophysiology of the heart, and in the maintenance of contractile functions by Ca(2+) regulation. In addition, due 
to the importance of sexual hormones in the regulation of metabolism and maintenance of cardiac function, the role of 
estrogen on different parameters has been analyzed. We focus on endothelial factors and NOD-, LRR, and pyrin domain-
containing 3 protein (NLRP3) modulation by estrogen. In conclusion, many molecular factors and cellular mechanisms that 
result in cardiovascular disease are different in men and women. Therefore, further research is necessary to enhance the 
understanding of all the sex related differences.
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Introduction
Cardiovascular diseases (CVDs) are the leading cause of 
death in Western countries with a relevant impact on public 
health (Virani et al., 2020). A series of factors play a role in the 
development of CVDs: lifestyle, environment, and different 
biological aspects such as sex, epigenetic factors, sex-specific 
gene expression, age, and hormonal status in pre- and post-
menopausal women. There are a lot of differences between 
men and women both in the susceptibility to these factors and 
in the pathophysiological mechanisms of CVDs. The role of 
sex in different pathological manifestations is not always clear 
and the underlying cause of these differences between males 
and females remains still unknown. Moreover, the prevalence 
and the mortality of CVDs appear different between men and 
women, thus stressing the necessity for gender and sex-specific 
intervention to address the gap in outcomes.
     For instance, a PubMed search for “cardiovascular 
diseases and sex” results in 7,394 review articles. If we 
search "cardiovascular diseases and sex" and "physiological 
mechanisms" the results are just 16 review articles (https://
pubmed.ncbi.nlm.nih.gov/?term=%22cardiovascular+disea
ses+and+sex%22+and+%22physiological+mechanisms%2
2&filter=pubt.review&sort=date; accessed on October 27th 
2020). Therefore, it appears that there is a high interest in sex 
differences in cardiovascular disease, but relatively few studies 
considered the physiology and pathophysiology at the basis of 
these differences. The main purpose of this short article is to 
examine sex differences in cardiovascular patho-physiology, 
report and briefly discuss representative aspects of sexual 
dimorphism and sex-related mechanisms.  Then we examine 
risk factors that may facilitate sex- and gender-specific quality 
care in CVDs. Finally, sex-related differences in the main CVDs 
are briefly considered.
Sexual dimorphism in cardiovascular physiology
Cardiovascular system anatomy
Focusing on the anatomy of the cardiovascular system, males 
and females share the same forming components, whose 
anatomy is not significantly different between the two sexes. 
In fact, the morphology and anatomical location of the heart, 
lungs, and major blood vessels are comparable in men and 
women (except for slight variations among individuals). 
However, a considerable difference between males and females 
exists in the size, and in particular, men have bigger hearts and 
vessels. The anatomical discrepancy in the heart size between 
males and females is not relevant, but it has important effects 
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on how they regulate cardiovascular function and homeostasis. 
It has been demonstrated that stroke volume (SV) is smaller 
in females, but this does not translate to significant differences 
in cardiac index (cardiac output (CO) per unit of body surface 
area) between the two sexes (Huxley, 2007). The reason is that 
women compensate for their smaller SV with a higher heart 
rate. This is a clear example of how men and women maintain 
homeostasis in different ways.
Autonomic nervous system
The relationship between the autonomic nervous system and 
the cardiovascular system is another way in which sexual 
dimorphism becomes evident. It has been demonstrated that 
females maintain a lower sympathetic tone on the heart at rest, 
with the parasympathetic system prevailing sharply. However, 
post-menopausal women show a relationship between markers 
of whole body sympathetic activity and vascular resistance, and 
sympathetic traffic rises progressively in both sexes with aging 
(Joyner et al. 2015). Yet, young men show a higher degree of 
sympathetic stimulation at rest both on the heart and on the 
vasculature, as demonstrated by the higher levels of circulating 
norepinephrine. The higher degree of parasympathetic 
stimulation at rest in females is believed to play a role in their 
increased susceptibility to orthostatic hypotension: when 
changing position from clinostatic to orthostatic, blood is pooled 
in the veins (especially those of the lower limbs) due to their 
capability to dilate, accommodating changes in volume with 
only minor changes in pressure. It causes a decrease in venous 
return to the heart, which in turn determines a transient decrease 
in CO. As a result, the baroreceptors are less stimulated 
and they withdraw the baroreflex, inducing a sympathetic 
discharge, which results in enhanced venous return to the heart 
and increased heart rate and contractility. This mechanism is 
usually swift, and these adjustments do not give any symptoms. 
However, females are more likely to experience the symptoms 
of orthostatic hypotension (such as dizziness, blurry vision, 
and even fainting), and this is believed to be a result of their 
reduced sympathetic tone at rest (among other causes, such 
as a lower muscle mass to help maintain a consistent venous 
return to the heart). Even under conditions of stress, such 
as when exercising, the cardiovascular systems of men and 
women respond differently. Several studies have shown that 
men respond to stress by increasing total peripheral resistance, 
whereas women respond by increasing the heart rate. In case 
of prolonged stress, men are subject to vessel remodeling and 
hypertension, whereas in women the extra workload is placed 
almost entirely on the heart.
Cardiac electrophysiology
One fascinating point about sexual dimorphism in humans 
concerns the electrophysiology of the heart. It has been 
observed that the QT interval of post-pubertal females is, on 
average, longer than that of males (Salama and Bett, 2014) 
and interestingly, this gap was not observed at birth nor in 
pre-pubertal individuals, suggesting the involvement of sex 
hormones. In fact, the QTc (i.e. the QT corrected for the heart 
rate) of males was found to shorten during puberty and then 
progressively lengthen with aging, resulting in males having the 
same QTc of females both during the pre-pubertal and senile 
ages. The duration of the QT interval is strictly dependent upon 
the duration of the action potential, and more specifically upon 
the duration of phases 2 and 3. Phase 2 is mostly regulated by 
the inward Ca(2+) current generated by L-type Ca(2+) channels, 
whereas phase 3 is regulated by the outward potassium currents 
generated by several K+ channels (rapid delayed rectifier K+ 
current [IKr], slow delayed rectifier K+ current [IKs], inward 
rectifier K+ current [Ik1]). Since testosterone and progesterone 
act on these channels in a nongenomic way, several studies have 
been conducted on the relationship between sexual hormones 
and QTc length (Sedlak et al., 2012). In particular, testosterone 
is known to shorten the action potential, by lowering the Ca(2+) 
current and increasing the potassium one; this results in an 
overall shortening of the QT interval. Similarly, interesting 
results have been reached analyzing the relationship between 
female sex hormones (estrogen and progesterone) and QTc. 
Estrogen has been found to have no impact on the length of QTc 
in humans, but progesterone seems to shorten the QT interval in 
females. It is demonstrated that women have cyclic variations 
in the QT interval corresponding to different phases of the 
menstrual cycle (Sedlak et al., 2012): in the luteal phase, in 
which there is a burst of progesterone, repolarizing K+ currents 
increases and the QT interval shortens. Despite the similar 
effects of testosterone and progesterone, post-pubertal males 
show a shortened QT in comparison to post-pubertal female; 
concordant to this, female hearts have shown a lower density 
of repolarizing K+ currents, i.e. a lower repolarization reserve, 
and more variance in the L-type Ca(2+) channels (Gaborit et al., 
2010).  This difference in the patterns of cardiac repolarization 
could explain why females have a longer action potential, 
resulting in a longer QT interval. The consequences for women 
are a sex-specific higher prevalence in cardiac arrhythmias 
such as the Torsade des pointes, a high-risk cardiac arrhythmia 
associated with long QT interval, and possible differences in 
responses to drugs used in the treatment of CVDs. Further 
study of the mechanisms that lead to QT length variation 
between the two sexes can be helpful in clarifying pathological 
implications.
     In summary, it seems evident that sexual dimorphism in 
humans is much more complex than it appears on the bare 
anatomical level. Males and females show different ways of 
regulating several pathophysiological processes, including 
neural control and electrophysiology features (Figure 1).
Sex-differences in pathophysiological mechanisms
Calcium regulation 
One of the fundamental mediators for heart function is Ca(2+), 
which is crucial for starting the contractile function and 
regulating the intensity of contractility at each beat. Ca(2+) 
is involved in the regulation of contractility, excitability, 
conductivity, and rhythmicity of the heart. Ca(2+) is also the 
leading factor in the regulation of metabolism, hypertrophic 
cell growth, and apoptosis, acting as a second messenger in 
signal transduction pathways (del Monte and Hajjar, 2003). 
Calcium handling alterations can lead to cell dysfunction and 
death and, consequently, to cardiac dysfunction and CVDs 
such as arrhythmias and heart failure. In the literature, several 
authors have addressed the difference in cell Ca(2+) management 
between men/males and women/females. Schwertz et al. (2004) 
examined these differences with different techniques using male 
and female Sprague-Dawley rats, and provided a specific picture 
of sex differences for the Ca(2+) sensitivity of contractile proteins 
and myofibrillar Ca(2+) transport in the myocardial ventricle. In 
particular, they have shown that there are sex divergences in 
the contractile ventricular response to extracellular Ca(2+) and 
they rely on the activity of all the Ca(2+) modulating proteins 
(channels, pumps, and transporters) that contribute in varying 
degrees to the availability of Ca(2+) for contractile proteins. 
Their work showed significant differences in Ca(2+)-stimulated 
Mg(2+)-dependent adenosine triphosphatase (ATPase) activity in 
isolated myofibrils from male and female rat heart ventricles. 
Specifically, they demonstrated that myofibrillar ATPase 
activity was higher in females than males and the Ca(2+) EC50 
for myofibrillar ATPase was significantly lower in female 
ventricular homogenate with respect to male's; therefore, Ca(2+) 
sensitivity of contractile proteins from female hearts is greater 
than contractile proteins from male hearts. Besides, at high 
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concentrations of Ca(2+) the rate of shortening and strengthening 
in isolated myocytes of female rats reaches a plateau while it 
continues to rise in male myocytes. In addition, they showed 
a greater influx of Ca(2+) current in female myocytes heart 
cells compared to male cells. These results provide scientific 
evidence for sex differences in Ca(2+) responsiveness and lead to 
a better understanding of  whether these alterations may be at 
the basis of mechanisms harmful to the contractile properties of 
myocardial cells.
     In recent years, research on sex-dependent differences on the 
susceptibility to CVDs has intensified, efforts analyzing aspects 
that have not yet been investigated. Fels and Manfredi (2019) 
analyzed sex differences in ischemia and reperfusion injury 
and the role of mitochondrial permeability transition pores 
(mPTPs), framing the study as a possible correlation between 
intracellular and intra mitochondrial Ca(2+) levels in response 
to ischemic and reperfusion injury and the protection provided 
by estrogen in preventing the opening of mPTPs. Indeed, the 
loss of Ca(2+) homeostasis represents a key point in the fate of 
cells and tissues that undergo ischemic stress, and the opening 
of mPTPs marks the border between life and death of cells. In 
summary, they showed that there is a different response in men 
and women to ischemic injury, and these differences lie in the 
modulatory effects of estrogen receptors. The sexual differences 
found in this study model highlighted the modulatory/protective 
effect of estrogen in the manipulation of Ca(2+) and in preventing 
the opening of mPTPs in ischemia and reperfusion.
Estrogen effects in cardiovascular pathophysiology
Menopause and sex hormone levels are thought to play a 
crucial role in the onset of CVDs; this assumption is based on 
the fact that the risk of many CVDs, such as atherosclerosis 
and hypertension, is significantly different in premenopausal 
and postmenopausal women (Table 1). In particular, a 
postmenopausal loss of cardioprotection is observed, suggesting 
a central role in sex hormones and, in particular, estrogen, on 
the cardiovascular system (Dosi et al., 2014). Estrogen is a 
steroid molecule that reaches quite high levels in females of 
reproductive age, but it is nevertheless present in all individuals 
at different concentration. Estrogen’s role in reproductive 
health is well known while its effect on other systems has been 
only investigated recently. Estrogen receptors ER-α and ER-β 
are present in many tissues and when they are activated, they 
dimerize and bind DNA response elements, which code for 
different proteins and macromolecules that can induce distinct 
cellular processes. Estrogen response is not always mediated 
by genetic expression, but rapid, non-nuclear signaling is also 
employed. For example, it has been shown that estrogen is 
able to bind to an orphan G-protein coupled receptor, GPR30, 
leading to rapid activation of kinase signaling pathways such 
as phosphatidylinositol 3-kinase (PI3K) and mitogen-activated 
protein kinase (MAPK) (Simoncini et al., 2000).  In Table 1, 
we summarize some of the protective effects of estrogen on the 
main factors that mediate cardiovascular pathophysiology.
Endothelial function
The maintenance of endothelial function plays an important 
role in the homeostasis of the cardiovascular system and 
endothelial dysfunction is a major cardiovascular risk factor 
associated with the majority of CVDs. In particular, endothelial 
dysfunction promotes the development of vascular diseases 
such as atherosclerosis, that is strongly associated with aging, 
hypertension, and hyperlipidemia (Davignon and Ganz 2004). 
The main alteration characterizing endothelial dysfunction is 
an imbalance in the activity of endothelial nitric oxide synthase 
(eNOS), which instead of leading to release of nitric oxide (NO) 
may release reactive oxygen species (ROS) (i.e. uncoupled 
NOS) (Lam et al., 2006; Morales et al., 2015). Indeed, estrogen 
therapy may restore vascular tetrahydrobiopterin levels and 
reduce oxidative stress in ovariectomized rats (Lam et al., 
2006). Besides that, other mechanisms are involved in the 
impairment of endothelial function, and differences between the 
two sexes may be relevant. 
     Endothelial cells extracted from men and women have 
shown different transcriptional profiles in normal conditions. 
In particular, female endothelial cells have higher expression 
of immune-related genes, including genes regulating the 
major histocompatibility complex (MHC), the complement 
system, and chemokine and cytokine release (Lorenz et al., 
2015). Endothelial dysfunction and related pathologies are 
directly correlated to inflammation of the endothelium (Galle 
et al., 2003); therefore, the understanding of sex differences 
in the immune gene profile may be pivotal in the discovery of 
sex differences in CVDs. Sex-specific expression patterns of 
endothelial cells were also found in response to shear stress, 
the force applied on the endothelial surface resulting from 
Figure 1. Main Factors Determining Sex-Related Differences in Cardiovascular Diseases.
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the friction of the blood on the vessel wall. In particular, a 
stronger flow-dependent vasodilation is characteristic of female 
endothelial cells, that are therefore more protected against 
endothelial dysfunction induced by oscillatory shear stress 
(Tremblay et al., 2019). Additional information regarding 
sex differences in endothelial function may be found in the 
recent review article by Stanhewicz et al. (2018). Overall, sex 
differences play important roles in the control of endothelial 
function and specific recommendations for the treatment or 
prevention of endothelial dysfunction and associated CVDs are 
needed for the mitigation of morbidity and mortality in men and 
women.
Nitric Oxide signaling 
It is well known that the vasodilator NO has protective 
effects on cardiovascular tissue, but it is still undetermined 
whether sexual differences are present in eNOS activity 
and NO function in endothelial cells. Cattaneo et al. (2017) 
studied the expression of eNOS in human male and female 
endothelial cells, and they found that female endothelial cells 
had higher eNOS mRNA and protein levels. NO signaling 
is enhanced by estrogen by different mechanisms, both by 
stimulating the expression of eNOS by increasing its activity 
via phosphorylation and by limiting eNOS uncoupling (Lam 
et al., 2006; Morales et al., 2015). Estrogen also upregulates 
eNOS through the classical genomic action of ER-α (Stanhewicz 
et al., 2018). Besides these mechanisms, estrogen infusion 
may induce a rapid vasodilation (in a few minutes) attributable 
to a concomitant increase in vascular cyclic adenosine 
monophosphate (cAMP) content (Barton, 2016). This suggested 
that estrogen could regulate vascular tone via a couple of 
non-genomic actions, including through the phosphorylation 
and activation of eNOS as a consequence of activation of 
PI3K signaling (Duckles and Miller, 2010). In addition, the 
downstream signaling of G-protein-coupled estrogen receptor 
(GPER), previously termed GPR30, may be another mechanism 
promoting eNOS activity in a non-genomic way. Indeed, G1, 
a selective GPER ligand, exerts cardiovascular effects through 
activation of the PI3K-Akt pathway and Notch signaling. It 
was recently reported that G1 may induce cardioprotection via 
Notch1 signaling and is able to reduce ischemia/reperfusion 
(I/R) injury in female hypertensive rats (Rocca et al., 2018). 
Finally, nitrergic nerves are of particular importance in the 
relaxation of corpus cavernosum and NO is known as the 
key factor involved in initiating and maintaining an erection 
(Förstermann & Sessa 2012). NO is involved in a plethora 
of pathophysiological mechanisms influenced by hormonal 
regulation and deserves to be further studied in relation to sex 
differences (Morales et al., 2015; Andreadou et al., 2020). 
Endothelial dependent hyperpolarization 
Other than the NO/cyclic guanosine monophosphate (cGMP) 
pathway, the regulation of the vascular tone is mediated also by 
another event, called endothelium-dependent hyperpolarization 
(EDH). EDH refers to the relaxation of vascular smooth 
muscle cells that occurs as a consequence of a hyperpolarizing 
stimulus, that in turn is promoted by the opening of the 
intermediate conductance calcium-activated potassium (IKCa) 
and small conductance calcium-activated potassium (SKCa) 
channels (Kong et al., 2015). These potassium channels open 
upon the elevation of intracellular Ca(2+) in endothelial cells, 
therefore EDH is stimulated by all ionotropic stimuli, such 
as acetylcholine. EDH represents a vasodilation mechanism 
that occurs independently of the production of endothelium-
derived NO. Physiologically the increased ability of a blood 
vessel to activate EDH occurs mostly when the NO signaling 
pathway is inhibited, i.e. in cases of endothelial dysfunction. 
It is hypothesized that EDH may intervene in endothelial 
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dysfunction to partially compensate for the loss of NO 
vasodilator effect (Ozkor et al., 2011). Despite this, during 
pathologic conditions such as aging and hypertension the ability 
to respond to endothelial dysfunction is reduced, and that is 
correlated with the fact that a selective reduction of EDH-
mediated relaxation has been observed (Ozkor et al., 2011). 
Again, estrogen may have a determining role in the modulation 
of EDH, as suggested by some evidence summarized in the 
review of Leung and Vanhoutte (2017). For example, in female 
rats 44–45 weeks old, as well as ovariectomized rats, mesenteric 
arteries showed a reduced EDH response and impaired 
relaxation (Liu et al., 2001). Instead, young females appear 
to have a stronger EDH response in parallel to an improved 
IKCa channel activity (Wong et al., 2014). The administration 
of 17β-estradiol to female rats subjected to ovariectomy is 
protective against vascular diseases, since it has been shown 
to improve EDH-type relaxations, other than NO vasodilation 
signaling (Chan et al., 2012).
Renin angiotensin system
Angiotensin-converting enzyme (ACE), the main enzyme 
involved in the renin angiotensin system (RAS), is able to 
convert angiotensin I to angiotensin II, which not only can 
induce systemic vasoconstriction and sodium retention, but 
also has a crucial role on a local level in tissues expressing the 
angiotensin II type 1 (AT1) receptor, including the heart and 
vessels (Lavoie and Sigmund, 2003). Angiotensin II induces 
processes such as fibrosis, hypertrophy, vasoconstriction, and 
increased ROS production. All these factors are involved in the 
mechanisms underlying coronary pathologies (which include 
systemic issues like hypertension and more tissue-specific ones 
such as fibrosis and inflammation).
     Women are protected from excessive activation of RAS, as 
demonstrated by the fact that they show lower ACE activity 
and expression, and lower AT1 receptor expression levels 
in comparison with men. That seems to be a consequence of 
the estrogen modulation of RAS. Indeed, estrogen is able to 
downregulate ACE and upregulate ACE2 expression, probably 
by targeting the promoter of these genes (Bukowska et al., 
2017). ACE2 can convert angiotensin II to angiotensin-(1-7), 
which upon the binding to Mas receptors, can in turn 
phosphorylate eNOS and Akt, thus increasing vasodilation and 
inhibiting apoptosis. Therefore, estrogen is able to drive the 
shift of RAS towards the formation of angiotensin (1-7), which, 
in contrast with angiotensin II, mediates protection against 
pathological cardiovascular conditions.
     To sum-up two counter-regulatory axes that form the RAS: 
the ACE/Angiotensin II/AT1 receptor axis the and ACE2/
angiotensin-(1-7)/Mas receptor axis. The binding of angiotensin 
II to the AT1 receptor mediates vasoconstriction, inflammation, 
fibrosis, and tissue injury. The binding of angiotensin-(1-7) 
to the Mas receptor limits proliferation, inflammation, and 
fibrogenic effects and, thus, promotes organ protection. It 
seems that females have the RAS balance towards the ACE2/
angiotensin-(1-7)/Mas receptor axis.
Metabolism  
Estrogens are able to modulate the energy balance through 
different mechanisms, acting on multiple tissues from the 
central nervous system to metabolism-regulating organs such 
as the adipose tissue, the muscle, the liver, and the pancreas. 
Regarding the central nervous system, the hypothalamus is 
the main site in which metabolic homeostasis is regulated. In 
particular, estrogen suppresses food intake by activation of ERα 
in the neurons of the arcuate nucleus and it promotes physical 
activity and controls body fat distribution though the stimulation 
of neurons in the ventromedial nucleus of hypothalamus (Xu 
et al., 2011). In these areas of the hypothalamus, ERα is co-
localized with the receptor for leptin, LEP-R (Diano et al., 
1998). Leptin is a hormone produced by adipose tissues 
with the aim to send catabolic signals to the brain, inhibiting 
food intake and limiting fat storage. It has been reported that 
estrogen, through a direct interaction on the LEP-R gene, down-
regulates the expression of the leptin receptor in the arcuate 
nucleus of the hypothalamus (Bennett et al., 1999). Therefore, 
estrogen is associated with increased leptin sensitivity, as 
demonstrated by the fact that ovariectomy reduces sensitivity 
to central leptin, that can be reversed by exogenous estrogen 
treatment. Exogenous estrogen administration increases leptin 
sensitivity in male rats (Clegg et al., 2006). According to these 
results, estrogen and leptin have a synergic action promoting 
energy expenditure and fighting fat accumulation, which in 
turn protect against metabolic alterations and obesity, relevant 
risk factors for CVDs. Another important effect on metabolism 
that could protect against CVDs, is the interaction of estrogen 
and insulin. Premenopausal women show increased insulin 
sensitivity compared with age-matched men, reflecting also 
the reduced incidence of type 2 diabetes mellitus (T2DM) 
in women (Park et al., 2003). In postmenopausal women or 
in ovariectomized patients, it is possible to observe a rapid 
decay in insulin sensitivity, along with fat mass elevation and 
increases in low-density lipoprotein (LDL), triglycerides, and 
fatty acids. These findings suggest that estrogen positively 
affects insulin action and protects against the development of 
T2DM in women. Estrogen effect on the lipid profile is also 
well known. It upregulates high-density lipoprotein (HDL) and 
downregulates LDL, shifting the lipid metabolism to an anti-
atherosclerotic profile, thus delaying eventual plaque formation 
in the coronary arteries (Palmisano et al., 2017). Lower LDL 
levels are achieved by increasing its clearance from plasma and 
upregulating LDL receptor on the surface of cells, while high 
HDL levels are a consequence of the decreased hepatic lipase 
activity and the increased synthesis of apolipoprotein, the major 
protein component of HDL particles in plasma (Guetta and 
Cannon, 1996). 
Inflammation 
Inflammation has a role in many pathological conditions 
that can contribute to the development of CVD, for example 
the inflammatory component of the atherosclerotic plaque 
is fundamental in the progression and final outcome of 
atherosclerosis. In particular, vascular inflammation plays a 
central role in initiating and perpetuating atherosclerotic and 
ischemic diseases, both in men and women (Shabbir et al., 
2020).  Estrogen is able to modulate inflammation through 
some mechanisms that occur upon activation of ERα, such 
as the inhibition of adhesion molecules such as E-selectin, 
intercellular adhesion molecule 1 (ICAM-1), vascular cell 
adhesion molecule 1 (VCAM-1), by decreasing the synthesis 
of pro-inflammatory molecules, and through activation of the 
degradation of damaged proteins through the proteasome (Villa 
et al., 2015) . For example, Ghisletti et al. (2005) investigated 
how estrogen was able to prevent the nuclear translocation 
of nuclear factor-kappa B (NF-κB), after lipopolysaccharide 
stimulation of mouse monocytes. They found that the 
blockage of this inflammatory mediator was exerted by a 
direct interaction of estrogen receptor with PI3K. Instead 
estrogen, through the transcriptional modulation of ERα, is 
able to downregulate the expression of some pro-inflammatory 
cytokines such as interleukin (IL)-6, tumor necrosis factor 
alpha (TNFα), and IL-1β (Shivers et al., 2015). Sex differences 
have been described in preclinical and experimental medicine 
studies in the inflammatory response and several recent 
studies underlined a clear sex difference in the resolution of 
inflammation, offering pharmacological opportunities for sex-
related therapies in coronary artery disease (CAD) (Reviewed 
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in Shabbir et al., 2020).
Inflammasome 
NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) 
the predominant inflammasome, is a high molecular weight 
complex present in the cytosol of variously stimulated cells. 
The assembled NLRP3 platform determines the activation of 
inflammatory caspases, in particular caspase-1, leading to the 
production of pro-inflammatory cytokines IL-1β and IL-18 
(Schroder and Tschopp, 2010). These cytokines may induce 
pro-hypertensive effects in endothelial cells and vascular 
smooth muscle cells, such as ROS production, endothelial 
dysfunction, and vasoconstriction (Krishnan et al., 2014). 
The NLRP3 inflammasome seems to play a pivotal role in the 
progression of many CVDs, specifically in the pathologies that 
are more affected by chronic inflammation and vascular damage 
such as hypertension, metabolic syndrome, and atherosclerosis 
(Mastrocola et al., 2018; Pasqua et al., 2018). For example, 
in rodent atherosclerosis models, the deletion of NLRP3 or 
other players of the inflammasome such as caspase-1, led to a 
significant reduction in atherosclerotic plaques (Duewell et al., 
2010).
     In the literature, evidence as to whether the NLRP3 
inflammasome is regulated differently in men and women is still 
scarce and should be integrated, but some insights are gathered 
below. It has been demonstrated that estrogen is able to drive 
the M2 phenotype polarization of macrophages (Keselman et 
al., 2017). The M1 phenotype is predominant in males, along 
with greater expression of NLRP3 and IL-1β. Cowie et al. 
(2019) demonstrated that after a surgical incision the production 
of NLRP3 mRNA was similarly increased in both males and 
females; despite this, following the deletion of NLRP3, the level 
of IL-1β was decreased only in males, suggesting that females 
have a NLRP3-independent mechanism of IL-1β production 
(Cowie et al., 2019).
     NLRP3 has been found to be regulated by estrogen during 
allergic airway inflammation, against which estrogen seems to 
have a protective effect (Matsubara et al., 2008). In the work 
of Cheng et al. (2019), ovariectomized mice sensitized with 
ovalbumin to establish airway inflammation, showed higher 
expression of the NLRP3 inflammasome and downstream 
effectors caspase-1 and IL-1β. The long term administration of 
17β-estradiol on the same mice markedly reduced ovalbumin-
induced airway inflammation and led to a suppression of both 
the mRNA expression and protein expression of NLRP3, 
caspase-1, and IL-1β (Cheng et al., 2019). Further studies 
are needed to elucidate the role of estrogen and to find the 
molecular pathways involved in the regulation of NLRP3 that 
are able to reduce inflammasome formation and inflammatory 
pathologies, including CVDs.
Fibrosis 
Cardiac fibrosis refers to a pathological remodeling of the 
extracellular matrix, as a consequence of aging, injury, or 
diseases. The fibrotic scars in the heart alter cardiac function, 
by thickening of the myocardial matrix or by impairing electric 
conductance, resulting in reduced ejection fraction (Hinderer 
and Schenke-Layland, 2019). Cardiac fibrosis is induced in 
fibroblasts by angiotensin II and endothelin-1, which stimulate 
transforming growth factor beta 1 (TGFβ1) synthesis, thereby 
activating c-Jun N-terminal kinase followed by Sma- and Mad-
related protein 3 phosphorylation, which in turn translocate to 
the nucleus and mediate the transition of the cardiac fibroblast 
to a myofibroblast phenotype, synthesizing procollagens I 
and III (Ruiz-Ortega et al., 2007). Estrogen seems to exert 
an anti-fibrotic action in cardiac fibrosis; in particular, it has 
been demonstrated that through cAMP and protein kinase 
A, estrogen is able to inhibit c-Jun N-terminal kinase and 
prevent myofibroblast formation. Estrogen administration in 
ovariectomized female mice, was able to prevent angiotensin 
II-induced cardiac fibrosis; this rescue was not observed in ERβ 
knockout rodents (Pedram et al., 2010).
Aging
Aging promotes some changes in the heart and blood vessels 
that predispose individuals to an increased risk of developing 
CVDs. Left ventricle (LV) chamber morphology, higher 
vascular stiffness, cardiomyocyte loss, and myocellular 
hypertrophy are age and sex-specific factors that can promote 
CVD onset, particularly in postmenopausal women (Oneglia et 
al., 2020). The role of aging and sex as modulators of I/R injury 
development, cardioprotection signaling, and efficacy of the 
therapeutic interventions has been reviewed elegantly by Ruiz-
Meana et al. (2019a). In this review intracellular and functional 
changes involved in I/R susceptibility and cardioprotection, as 
well as variations in inflammatory cells, and in extracellular 
matrix during aging, have been analyzed. Of note, aging induces 
a certain mismatch in the cell energy supply and demand, 
which may be secondary to deficient sarcoplasmic reticulum-
mitochondria Ca(2+) exchange and defective supramolecular 
assembly of the respiratory chain supercomplexes. Whether 
this Ca(2+) handling is different between sexes is unclear. Also 
inadequate transfer of intracellular energy and progressive 
metabolic remodeling (i.e., partial replacement of OXPHOS by 
glycolysis) have been proposed as a central mechanism of aging 
(Fernandez-Sanz et al., 2014; Ramirez-Camacho et al., 2019; 
Ruiz-Meana et al., 2019a, 2019b). Whether these mechanisms 
influence the outcome of CAD in aging patients of both 
sexes remains to be ascertained. Nevertheless, cardiomyocyte 
death rates during aging increases to a greater extent in men 
compared to women, and this is probably due to the fact that 
women have a greater pool of cardiac stem cells, as well as a 
lower myocyte turnover in comparison to men. On the other 
hand, women during aging show increased vascular stiffening, 
an event that is dependent on a series of factors including 
endothelial dysfunction, elastin-collagen content, inflammation, 
and neurohormonal signaling (Oneglia et al., 2020). 
Risk factors, gender, and sex
Cardiac risk factor management may be a smart strategy to 
decrease overall the rates of CVDs in both men and women. 
Other than the conventional risk factors such as hypertension, 
diabetes, smoking, and dyslipidemia, it is important to evaluate 
the risk related to healthcare, and social and cultural behaviors. 
The sex-specific susceptibility to these factors is not easy to 
determine, but it is fundamental to improving the prevention, 
diagnosis, treatment, and prognosis of CVD.
     Men and women may be exposed to different cardiac risk 
factors. For instance, men are more susceptible than women to 
unfavorable risk factors including smoking, low-fiber diet, and 
low vitamin C levels, while women are more prone to diabetes 
mellitus, hypertension, hypercholesterolemia, and obesity 
(Manfrini et al., 2020). CVD is estimated to be responsible 
for approximately 65% of deaths in diabetic patients, and the 
relative mortality risk from CVDs is higher in women with 
diabetes than in men (Harreiter et al., 2020). Besides, diabetic 
women show a 3- to 7-fold increased CVD onset risk compared 
with a 2- to 3 fold elevated risk in men; despite this, evidence in 
the literature are controversial, as pointed out in the systematic 
review by Chase-Vilchez et al. (2020), in which they show 
that diabetes is not associated with a higher risk in women for 
peripheral arterial disease compared to men (Chase-Vilchez et 
al., 2020).
     Social and psychological aspects can have a relevant impact 
on the determination of sex/gender differences in CVDs.  First 
of all, women are less aware that heart disease is a leading 
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cause of death for them and they are also less informed about 
the typical clinical manifestation of CVDs. The recognition 
of symptoms of myocardial infarction (MI) for women can 
be more challenging, because often they do not experience 
the typical chest pain, instead MI in women is characterized 
by non-specific symptoms such as abdominal pain, dyspnea, 
nausea, back and neck pain, and palpitations (Stehli et al., 
2020). That could be the reason why women experience longer 
time from the MI onset to hospital admission. The time between 
symptoms presentation and treatment affects patient outcome 
in cases of MI. Besides women, compared to men, are less 
prone to undergo invasive diagnostic testing or percutaneous 
coronary intervention (Manfrini et al., 2020). All of these 
factors can contribute to the poorer cardiovascular outcomes 
that often affect women more than men. Sex and gender specific 
prevention and diagnosis could be the first steps in order to 
partially fill this gap.
Sex-related differences in the main CVDs
Atherosclerosis and CAD 
Atherosclerosis is a condition characterized by narrowed and 
hardened arteries as a consequence of the formation of lipid 
plaques. At a younger age, men are more susceptible to develop 
atherosclerosis than women, but it has been observed that in 
the elderly the prevalence for women increases, in particular in 
the presence of autoimmune diseases (Fairweather, 2014). The 
explanation is that sex hormones, inflammation, lipid profile, 
shear stress, and all other risk factors common in CVDs such 
as obesity, smoke, and life style, can expose both sexes to 
atherosclerosis risk in different ways (Shabbir et al. 2020). Men 
are affected more by occlusive CAD, while women suffer more 
from the nonobstructive form. In men, CAD is mainly due to 
atherosclerosis of coronary epicardial arteries, while in women 
CAD is a consequence of pathological vasoreactivity, such 
as spasm and endothelial dysfunction (Regitz-Zagrosek and 
Kararigas, 2017). 
Hypertension
Globally, it was estimated that 31.1% of the world’s population 
is affected by hypertension (Mills et al., 2020). Hypertension 
represents the primary reversible risk factor in the development 
of CVD. It has been observed that blood pressure in men 
is higher than women, resulting in a higher prevalence of 
hypertension in young men (Ramirez and Sullivan, 2018). 
Despite this, in older individuals the percentage of hypertensive 
women reaches that of men. This may be a consequence of the 
change in the hormonal status of pre- and post-menopausal 
women (Nwankwo et al., 2013). Both in women and in men, 
the development of hypertension is often correlated with 
diabetes and metabolic syndromes (Henry et al., 2012). Clearly, 
the metabolic syndrome accelerates arterial aging and amplifies 
hypertension-related cardiac and renal alterations. Studies from 
all over the world support this association between sex, age, 
hypertension and the related complications (e.g. Campbell et 
al., 2020).
Myocardial infarction 
It has been observed that myocardial infarction has a higher 
impact on mortality in women than age-matched men (Johansson 
et al., 2017). Also experimental studies have shown a substantial 
difference in myocardial I/R injury susceptibility between 
the two sexes (Penna et al., 2009). MI in women is often a 
consequence of plaque erosion compared with the plaque 
rupture that occurs most of the time in men and older women 
(Stehli et al., 2020). Another cause of MI typically detected 
in women rather than men is the spontaneous coronary artery 
dissection, that determines an infarction event in up to 25% of 
women younger than 60 years of age. Besides, the coronary 
arteries of women are more susceptible to microvascular 
dysfunction and impaired coronary flow reserve compared to 
vessels in men (Taqueti et al., 2018). Women mortality post 
MI is more frequently associated with cardiac rupture, while 
arrhythmia is the main complication leading to death in men 
(Mirić et al., 2008). These observations on mortality do not 
depend on the type of treatment used. Moreover, heart failure 
(HF) following MI is more frequent in women than in men.
Heart failure
Regarding heart failure, which is often a complication of MI, 
some observations indicate the presence of peculiar differences 
between women and men. In particular, women are mainly 
affected by HF with preserved ejection fraction (HFpEF). On 
the contrary, HF with reduced ejection fraction is typically 
found in men (Regitz-Zagrosek et al., 2007). According to 
many authors, the analysis of a series of physiological and 
mechanical properties of the heart, such as ventricular diastolic 
distensibility, vascular stiffness, ventricular/vascular coupling, 
and skeletal muscle adaptation to HF, is useful to describe the 
main sex differences in HF. Campbell et al. (2019) focused on 
the threshold of body mass index (BMI) and sex-specific waist 
circumference on the increased risk of HFpEF. They proposed 
different caist circumference and BMI thresholds for the 
increased incidence of HFpEF that may be useful for prevention 
strategies. The waist circumference thresholds of 100 cm or 
less in men and 90 cm or less in women and a BMI threshold 
of 27.5 kg/m2 or less were demonstrated from this study as a 
cutoff point.  The BMI and waist circumference below these 
thresholds may reduce the incidence rate of HFpEF by about 
50%. Sex differences in HF have been recently reviewed by 
Lam et al. (2019). 
COVID-19 and Sex
The virus responsible for coronavirus disease 2019 (COVID-19) 
binds to ACE2 and the pathophysiology of COVID-19 infection 
might rely on a large extent on imbalance of the RAS. As 
many CVDs display an unbalance of RAS, COVID-19 may 
be considered a pneumonia highly associated with CVDs or a 
systemic disease (Pagliaro and Penna, 2020; Penna et al., 2020). 
It has been shown that COVID-19 has the worst outcomes 
when present in individuals with pre-existing cardiovascular 
pathologies, in particular the most frequent comorbidities are 
hypertension (15.6%), diabetes (7.7%), and CVDs (4.7%) 
(Lumpuy-Castillo et al., 2020; Moccia et al.,  2020). The 
severity and lethality of COVID-19, as measured by admission 
to intensive care units and the death prevalence, have been 
reported to be about 2 times greater for men than for women 
worldwide (Penna et al., 2020; Richardson et al., 2020). These 
data suggest that sex plays a role in COVID-19 severity and 
that women of all ages are protected against COVID-19. In 
particular, among COVID-19 affected patients, fewer women 
than men presented with cardiac damage, but those women with 
cardiac damage had higher levels of systemic inflammatory 
markers, suggesting a male inflammatory phenotype (Shi et 
al., 2020). We also believe that COVID-19 sex differences 
should be taken into account because they could reveal specific 
therapeutic approaches, useful to improve outcomes for both 
sexes.
Conclusions
In conclusion, males and females exhibit some differences 
in the cardiovascular anatomic structures, electrophysiology, 
autonomic nervous system, metabolism, inflammation, and 
in some molecular mechanisms such as Ca(2+) homeostasis, 
NO signaling, NLRP3, and RAS. It is well established that 
sex hormones, in particular estrogen, play a crucial role in 
regulating all these processes. Estrogen decline after menopause 
results in changes that predispose post-menopause women to 
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CVD, such as reduced insulin and leptin responsiveness, altered 
lipid profile, and increased inflammatory state, which in turn 
increase the risk for obesity and diabetes, higher propensity 
to fibrosis, enhanced blood pressure and others. Therefore, 
along with all the traditional risk factors for CVD, menopause, 
especially the early onset form, represents a sex-specific risk 
factor. In recent years, many researchers investigated the 
possibility to reverse the negative effect of menopause with 
hormone replacement therapy. Although this treatment has been 
effective, it has not demonstrated a clear protective effect on 
the development of CVD. This suggests that research should 
be focused on new mechanisms that result in CVD differences 
in men and women. The knowledge of sex differences may 
be useful for both women and men, and efforts are also 
needed to bring sex and gender to the attention of modern 
medical research, clinical practice, and biomedical education. 
This research, with an accurate re-evaluation of diagnostic 
procedures, could lead to a more efficient management of all 
patients. In conclusion, physicians should be aware of these 
issues and educate medical students and patients for a future 
greater awareness of sex and gender differences in CVDs.
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